Shear Stress and ROS Dual-Responsive RBC-Hitchhiking Nanoparticles for Atherosclerosis Therapy
Source abstract
Abstract
Atherosclerosis (AS), a leading cause of death worldwide, is a chronic inflammatory disease rich in lipids and reactive oxygen species (ROS) within plaques. Therefore, lowering lipid and ROS levels is effective in treating AS and reducing AS-induced mortality. In this study, an intelligent biomimetic drug delivery system that specifically responded to both shear stress and ROS microenvironment was developed, consisting of red blood cells (RBCs) and cross-linked polyethyleneimine nanoparticles (SA PEI) loaded with a lipid-lowering drug simvastatin acid (SA), and RBCs were self-assembled with SA PEI to obtain biresponsive SA PEI@RBCs for the treatment of AS. SA PEI could achieve sustained release of SA in response to ROS and reduce ROS and lipid levels to achieve the purpose of treating AS. Shear stress model experiments showed that SA PEI@RBCs could respond to the high shear stress level (100 dynes/cm 2 ) at plaques, realizing the desorption and enrichment of SA PEI and improving the therapeutic efficiency of SA PEI@RBCs. In vitro and in vivo experiments have confirmed that SA PEI@RBCs exhibits better in vivo safety and therapeutic efficacy than SA PEI and free SA. Therefore, shaping SA PEI@RBCs into a biomimetic drug delivery system with dual sensitivity to ROS and shear stress is an effective strategy and treatment to facilitate their delivery into plaques.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Blood properties and coagulation · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun 130012, Jilin, China
Department of Radiation Oncology, China−Japan Union Hospital of Jilin University, Changchun 130031, Jilin, China
Department of Blood Purification, Tong Liao City Hospital, Tong Liao 028000, Inner Mongolia, China
Department of Oncology and Hematology, China−Japan Union Hospital of Jilin University, Changchun 130031, Jilin, China
Funding
Jilin University · Jilin University Bethune Medical Department
References (63)
Show source-provided references
1. 10.1172/JCI9795010.1172/JCI97950 ↗
2. Libby, P.; Hansson, G. K. Taming Immune and Inflammatory Responses to Treat Atherosclerosis; American College of Cardiology Foundation: Washington, DC, 2018; Vol. 71, pp 173–176.10.1016/j.jacc.2017.10.081 ↗
3. 10.1161/CIR.000000000000035010.1161/CIR.0000000000000350 ↗
4. 10.1161/CIR.000000000000048510.1161/CIR.0000000000000485 ↗
5. 10.1021/acsnano.8b0887510.1021/acsnano.8b08875 ↗
6. 10.1371/journal.pone.000885210.1371/journal.pone.0008852 ↗
7. 10.1002/wnan.141210.1002/wnan.1412 ↗
8. 10.1002/jbt.2198110.1002/jbt.21981 ↗
9. 10.12968/hosp.2000.61.11.146510.12968/hosp.2000.61.11.1465 ↗
10. 10.1007/s00228-006-0097-z10.1007/s00228-006-0097-z ↗
11. Vickers S. · Drug Metab. Dispos. · 1990 · 18 · 476
12. 10.2174/1570159X1566617070310181610.2174/1570159X15666170703101816 ↗
13. 10.1016/j.pcad.2016.07.00910.1016/j.pcad.2016.07.009 ↗
14. 10.1021/jacs.0c0902910.1021/jacs.0c09029 ↗
15. 10.1002/anie.20201441510.1002/anie.202014415 ↗
16. 10.1021/acs.nanolett.1c0480410.1021/acs.nanolett.1c04804 ↗
17. 10.1016/j.chempr.2022.03.00910.1016/j.chempr.2022.03.009 ↗
18. 10.1002/anie.20211722910.1002/anie.202117229 ↗
19. 10.1002/anie.20211042710.1002/anie.202110427 ↗
20. 10.1016/j.chempr.2020.06.02410.1016/j.chempr.2020.06.024 ↗
21. 10.1016/j.biomaterials.2017.07.03510.1016/j.biomaterials.2017.07.035 ↗
22. 10.1016/j.nano.2018.06.01010.1016/j.nano.2018.06.010 ↗
23. 10.1002/adma.20190460710.1002/adma.201904607 ↗
24. 10.1001/jama.282.21.203510.1001/jama.282.21.2035 ↗
25. 10.1039/D1QI00026H10.1039/D1QI00026H ↗
26. 10.1016/j.biomaterials.2009.11.01210.1016/j.biomaterials.2009.11.012 ↗
27. 10.1016/j.carbpol.2019.11512810.1016/j.carbpol.2019.115128 ↗
28. 10.1016/j.ijbiomac.2019.02.03610.1016/j.ijbiomac.2019.02.036 ↗
29. 10.1021/nn404853z10.1021/nn404853z ↗
30. 10.1016/j.ymeth.2006.05.01610.1016/j.ymeth.2006.05.016 ↗
31. 10.2478/s11756-013-0207-110.2478/s11756-013-0207-1 ↗
32. 10.1016/j.ijpharm.2015.10.04610.1016/j.ijpharm.2015.10.046 ↗
33. 10.1365/s10337-009-1432-110.1365/s10337-009-1432-1 ↗
34. 10.1007/s00726-015-1983-410.1007/s00726-015-1983-4 ↗
35. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
36. 10.1016/j.msec.2019.11039610.1016/j.msec.2019.110396 ↗
37. 10.1039/c1ob05886j10.1039/c1ob05886j ↗
38. 10.1016/j.actbio.2017.06.03710.1016/j.actbio.2017.06.037 ↗
39. 10.1016/j.actbio.2014.09.04710.1016/j.actbio.2014.09.047 ↗
40. 10.1039/c3tb21241f10.1039/c3tb21241f ↗
41. 10.1021/acsami.9b2288110.1021/acsami.9b22881 ↗
42. 10.7150/thno.7888410.7150/thno.78884 ↗
43. 10.1021/acs.chemmater.0c0408010.1021/acs.chemmater.0c04080 ↗
44. 10.1021/acs.nanolett.8b0073710.1021/acs.nanolett.8b00737 ↗
45. 10.1182/blood.V126.23.653.65310.1182/blood.V126.23.653.653 ↗
46. 10.1039/D0NR01236J10.1039/D0NR01236J ↗
47. 10.1007/s10856-019-6336-510.1007/s10856-019-6336-5 ↗
48. 10.1002/smll.20180185210.1002/smll.201801852 ↗
49. 10.1016/j.freeradbiomed.2016.07.00310.1016/j.freeradbiomed.2016.07.003 ↗
50. 10.1080/10715762.2018.145721710.1080/10715762.2018.1457217 ↗
51. 10.1126/sciadv.aao671810.1126/sciadv.aao6718 ↗
52. 10.1016/j.redox.2017.05.00710.1016/j.redox.2017.05.007 ↗
53. 10.1002/anie.20180505210.1002/anie.201805052 ↗
54. 10.3858/emm.2011.43.11.06710.3858/emm.2011.43.11.067 ↗
55. 10.1038/nnano.2012.8410.1038/nnano.2012.84 ↗
56. 10.1182/blood-2018-99-11394810.1182/blood-2018-99-113948 ↗
57. 10.1016/j.addr.2023.11489510.1016/j.addr.2023.114895 ↗
58. 10.1111/1750-3841.1478610.1111/1750-3841.14786 ↗
59. 10.1016/j.addr.2016.02.00710.1016/j.addr.2016.02.007 ↗
60. 10.1111/jgh.1265710.1111/jgh.12657 ↗
61. 10.1021/acsami.7b1009810.1021/acsami.7b10098 ↗
62. 10.1111/imj.1246410.1111/imj.12464 ↗
63. 10.1016/j.jemermed.2005.08.02010.1016/j.jemermed.2005.08.020 ↗